AbbVie ABBV · NYSE
$286.76 +0.13% (+$0.37)
Summary
48 / 100 · Bulios Score
What speaks for it
- It has raised its dividend 12 years in a row.
- Out of every 100 USD of revenue, 31 USD is left as free cash.
- It earns 13 USD a year on every 100 USD of invested capital.
- Analysts expect revenue to grow by 10% this fiscal year.
What to watch
- It pays out more in dividends than it earns: 194% of profit.
- Earnings per share fell by 29% a year over the last 3 years.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 80.2 USD for 1 USD of yearly profit. Over the last five years it was 54.2 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.0% a year over 5 years. Over the last 3 years it grew by 1.8% a year. For the next fiscal year analysts expect revenue to grow by 10%. Earnings per share fell by 29% a year over the last 3 years.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 29 USD
- Research and development 15 USD
- Sales and administration 27 USD
- Taxes and other 20 USD
- Net profit 9.8 USD
Net profit, industry median (Drug Manufacturers - General) 14 USD
Out of every 100 USD of revenue, 9.8 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 3.6 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 2.42%
- Paid out of profit
- 194%
- Raised in a row
- 12 years
You receive $6.92 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 31
- Hold 12
- Sell 1
Today's price within the analysts' price targets
The average target of $290.43 is 1.3% above today's price. 70% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- SKYRIZI 30%
- RINVOQ 14%
- H U M I R A 7.8%
- Botox Therapeutic 6.5%
- Vraylar 6.2%
- Other 35%
By region
- UNITED STATES 95%
- Non-US 4.8%
SKYRIZI brings in 30% of revenue.
Segments in detail